Format

Send to

Choose Destination
Haemophilia. 2010 Jul;16 Suppl 6:1-2. doi: 10.1111/j.1365-2516.2010.02298.x.

Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.

Author information

1
Mount Sinai School of Medicine, New York, NY 10029, USA. louis.aledort@mountsinai.org

Abstract

Hemophilia A and B are traditionally thought of as a single bleeding disorder, viewed as opposite sides of the same coin. Yet the differences between the 2 forms of congenital hemophilia extend far beyond the type of deficient clotting factor--factor VIII for hemophilia A and factor IX (FIX) for hemophilia B. This supplement focuses on the unique laboratory and clinical issues associated with FIX replacement therapy for children and adults with hemophilia B.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center